Drug intelligence / Profile preview

Akkermansia muciniphila p*-βL strain

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Akkermansia muciniphila p*-βL strain is a specific strain of the Gram-negative, anaerobic bacterium Akkermansia muciniphila, belonging to the phylum Verrucomicrobia. The p*-βL designation appears to refer to a variant with a TEM-type β-lactamase gene promoter or related antibiotic resistance determinant. Akkermansia muciniphila is recognized as a next-generation probiotic with demonstrated strain-specific effects on host metabolism, immune modulation, and gut barrier integrity. Specific strains show potential in managing obesity, metabolic disorders, and inflammation, with evidence suggesting modulation of cytokines, gut microbiota normalization, tight junction protein expression, and short chain fatty acid production, but the p*-βL strain specifically is associated with altered phenotypes after antibiotic selection, such as reduced anti-obesity effect. Development is ongoing for differentiated clinical applications, but strain-dependent effects are critical, and clinical impact can vary[5][1][3][7].

Targets

Class A BL (Class A beta-lactamase)MUC2 (Mucin-2)

Beyond the preview

Go deeper on Akkermansia muciniphila p*-βL strain.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akkermansia muciniphila p*-βL strain.

Explore the full profile